Powered by:


EuroNanoMed 3/2018-phase II

A consortium of 5 partners from Greece, France, Italy and Turkey coming from academia & the public health sector are preparing a full proposal on "Development of new nano-immunomedicines for Alzheimer?s disease" for the EuroNanoMed 3/2018 call. They are urgently looking for a biotech SME from Spain, Latvia or Lithuania with expertise in the large-scale production of monoclonal antibodies or specialized in the production of polymeric nanoparticles or liposomes.

Partnership(s) sought
  • Research cooperation agreement
Descripción completa

A consortium consisting of 5 partners from 4 countries (Greece, France, Italy and Turkey) involving research groups from both academia and the clinical/public health research sector has recently submitted a pre-proposal for the category ?Innovation applied research projects?, which passed the first evaluation step successfully and is now being submitted at the full proposal submission stage for the EuroNanoMed 3/2018 call.

The proposal aims to advance the development of effective immunotherapy for Alzheimer?s disease (AD) based on the use of nanoparticles. The current consortium members have significant expertise in nanotechnology, molecular biology, immunology and neurobiology, which is necessary for the proposal?s implementation.

They seek one additional partner, an SME, specifically from either Spain, Latvia or Lithuania.

They are urgently looking for:
1. A biotechnology SME capable of designing and implementing the large-scale production of monoclonal antibodies under GMP (Good Manufacturing Practice) conditions
2] a pharmaceutical or biotechnology SME specialized in the production of polymeric nanoparticles or liposomes

More information about the research proposal will be provided upon selection.

Call deadline: 30/05/2018
Deadline for Expressions of interest: 14/05/2018

Socio buscado:

- Specific area of activity of the partner: The consortium is urgently looking for:

1. A biotechnology SME to undertake the large-scale production - under GMP conditions - of the developed monoclonal antibodies against the two main target neuroantigens


2. A pharmaceutical or biotechnology SME which will design and implement a larger (than lab) scale manufacturing process for the nanocarriers (polymeric nanoparticles or liposomes).

The selected SME will enter the consortium that will submit a joint full proposal for the EuroNanoMed 3/2018 call with deadline 30/05/18.

Development Stage:

Proposal under development

Programme - Call:

Evaluation scheme: Innovation applied research projects


Deadline: 30/05/2018

Coordinator required: No

» Reference: full proposal

» More Information

« Go to Technological Watch


[16/01/2019] - Final Places for Fire Performance Event

[16/01/2019] - Six new substances added to the Candidate List

[16/01/2019] - Web Industries names Mark Pihl chief executive officer

[16/01/2019] - Nestlé Accelerates Action to Tackle Plastic Waste

This project has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n° [310187].